Treatment with peginterferon alfa-2a (40KD) (PEGASYS) of chronic hepatitis B patients, who have failed anti-viral treatment. A pilot study.

Trial Profile

Treatment with peginterferon alfa-2a (40KD) (PEGASYS) of chronic hepatitis B patients, who have failed anti-viral treatment. A pilot study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2013

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2010 Actual patient number (50) added as reported by ClinicalTrials.gov.
    • 09 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jun 2010 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top